Exon 20 Insertion Mutant EGFR-Based Detection and Monitoring Systems
Legal Citation
Summary of the Inventive Concept
The inventive concept applies the core technology of selective inhibitors of exon 20 insertion mutant EGFR to develop innovative detection and monitoring systems for various industries, including wildfire detection, water quality monitoring, invasive species tracking, agricultural pest control, and neurological disorder diagnosis.
Background and Problem Solved
The original patent focused on antitumor agents for treating cancers with EGFR having exon 20 insertion mutations. However, the detection and monitoring of such mutations have broader applications beyond cancer treatment. The new inventive concept addresses the need for efficient and accurate detection methods in various fields, leveraging the core technology of the original patent.
Detailed Description of the Inventive Concept
The inventive concept encompasses a range of systems and methods that utilize exon 20 insertion mutant EGFR-based detection methods. For instance, a wildfire detection system can employ sensors to detect EGFR having exon 20 insertion mutations in environmental samples, triggering alerts to firefighters. Similarly, a water quality monitoring system can detect EGFR mutations in water samples to generate reports on water quality. The inventive concept also extends to invasive species tracking, agricultural pest control, and neurological disorder diagnosis, where the detection of EGFR mutations enables targeted interventions and treatments.
Novelty and Inventive Step
The new claims introduce novel applications of exon 20 insertion mutant EGFR-based detection methods, moving beyond cancer treatment to address pressing issues in various industries. The inventive step lies in the recognition of the broader potential of this technology and its adaptation to new fields, resulting in innovative solutions that were not obvious from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the development of portable detection devices, integration with existing monitoring systems, or the use of machine learning algorithms to enhance detection accuracy. Variations of the inventive concept could also explore the application of exon 20 insertion mutant EGFR-based detection methods to other fields, such as environmental monitoring or forensic analysis.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential across multiple industries, including environmental monitoring, agriculture, and healthcare. The market for such detection and monitoring systems is substantial, driven by the need for efficient and accurate solutions to pressing problems in these fields. The inventive concept offers a unique value proposition, enabling the development of innovative products and services that can address these needs and create new business opportunities.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/519 |
| A | A61 | A61P35/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular biology, oncology, and diagnostic technologies with a focus on genetic mutation detection and targeted therapeutic interventions
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology, biotechnology, or biomedical engineering, possessing expertise in genetic mutation analysis, diagnostic sensor technologies, and interdisciplinary application of molecular detection methods
Obviousness Rationale
A person having ordinary skill in the art would recognize the fundamental principle of EGFR mutation detection as a versatile diagnostic technique that could be readily adapted to multiple domains beyond cancer treatment. The source patent's core technology of detecting and targeting exon 20 insertion mutations provides a clear technological framework that can be systematically extended to other detection and monitoring applications. The PTD's variations represent predictable extrapolations of the original detection methodology using standard sensor and diagnostic technologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,513 |
|---|---|
| Title | Selective inhibitor of exon 20 insertion mutant EGFR |
| Assignee(s) | TAIHO PHARMACEUTICAL CO., LTD. |